Utah Medical Products posted 2Q 2026 revenue of $1.424 million, a 14.3% drop versus a year earlier, while 1H revenue fell 12.3% to $2.411 million. The decline, driven by loss of its two top customers, trims top‑line growth and pressures margins, signaling tighter earnings outlook for investors.
Key Highlights
- 2Q 2026 revenue $1.424 million, down 14.3% year‑over‑year.
- 1H 2026 revenue $2.411 million, down 12.3% versus 2025.
- Gross profit margin slipped to 55.8% from 56.2% in the prior year.
- Cash and investments rose to $87.5 million, up from $85.8 million at year‑end.
Utah Medical Products (NASDAQ: UTMD) posted sharply lower sales for the second calendar quarter, with consolidated revenue of $1.424 million, a 14.3% decline from the same period a year earlier. The first half of the year also slipped, totaling $2.411 million, representing a 12.3% drop versus 2025. Comparable earnings per share for the March‑ended quarter of 2024 stood at $1.09, underscoring the contrast with the present earnings environment.
With zero sales to those accounts in 2Q 2026, the firm’s worldwide sales of $8.529 million fell sharply. Domestic sales slumped 11.9% to $5.166 million, while overseas sales dropped 17.7% to $3.363 million. The loss of high‑volume OEM contracts has left the company scrambling to replace revenue streams, a challenge that could linger if new contracts fail to materialize.
Margin Pressures
Gross profit margin contracted to 55.8% from 56.2% a year earlier, a modest erosion that masks steeper operating income pressure. Despite a slightly higher net income margin of 31.5% versus 30.6% in the prior year, the absolute profit declined alongside revenue, indicating that cost discipline has not fully offset the top‑line weakness. The margin squeeze suggests that any future revenue rebound will need to be paired with tighter expense control to protect earnings.
Balance Sheet Resilience
Cash and investments rose to $87.5 million from $85.8 million at the end of 2025, bolstered by a $2.0 million cash dividend and a modest $0.2 million share repurchase. Working capital improved by $1.7 million, driven by a $1.1 million inventory buildup and a $0.5 million reduction in current liabilities. Capital expenditures were limited to $0.3 million, underscoring a cautious approach to spending.
The company remains debt‑free, positioning it to weather the ongoing sales decline, yet the modest cash increase does little to offset the revenue shortfall, leaving investors to monitor liquidity closely. Short interest sits at 4% of outstanding shares, requiring 6.8 days of average volume to cover, a neutral indicator of market sentiment. The revenue dip and margin compression have placed pressure on earnings expectations, and the upcoming August 2026 Form 10‑Q filing will provide the next detailed performance snapshot.
Investors should watch that filing for any revisions to the company’s 2026 sales guidance, which currently projects a 10‑13% decline versus 2025.
Analysis based on the Form 8-K filed 23 July 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...